Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better describe the condition's systemic nature [1, 2, 3].
This change is intended to shift the clinical focus from the ovaries to the broader metabolic and endocrine disruptions that characterize the disorder. By updating the terminology, researchers and clinicians aim to improve the quality of care and the direction of medical research for those affected.
Dr. Helena Teede, a leading researcher on the condition, is one of the primary doctors behind the name change [1, 5]. The transition to PMOS acknowledges that the disorder is not limited to the reproductive system but is a complex metabolic issue.
The scale of the condition is significant. Estimates indicate that PMOS affects one in eight women worldwide [2, 4]. Some reports suggest the global impact reaches approximately 170 million women [6]. In Canada, the condition is estimated to affect one in 10 women [6].
The renaming is being communicated on a global scale. Coverage of the shift has appeared in the United Kingdom, the U.S., and Canada [4, 7]. The move is designed to reduce the misconception that the condition is solely an ovarian issue, a misunderstanding that has historically hindered comprehensive treatment.
Medical professionals said that the new name will help patients receive more holistic care. By emphasizing the "polyendocrine" and "metabolic" aspects, the term PMOS encourages doctors to look beyond the ovaries and address the hormonal and metabolic imbalances throughout the body [4, 7].
“Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS)”
The transition from PCOS to PMOS represents a paradigm shift in how the medical community views the disorder. By removing the primary emphasis on 'cysts' and 'ovaries,' the new terminology steers clinicians toward treating the condition as a systemic metabolic disorder rather than a localized reproductive issue. This is likely to influence future diagnostic criteria and the development of treatments that target endocrine health more broadly.
